Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Taylor, Stanford
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24
NCT05930561: 4D-150 in Patients With Diabetic Macular Edema	Recruiting	2	72	US	4D-150 IVT, Aflibercept IVT, Eylea	4D Molecular Therapeutics	Diabetic Macular Edema, Diabetic Retinopathy	02/28	07/28
Haw, Weldon
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24
Sackel, David
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24
Wynne, Kathy
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24